106
Participants
Start Date
October 27, 2016
Primary Completion Date
October 23, 2017
Study Completion Date
October 25, 2019
Nivolumab
-Specified dose on specified days
Ipilimumab
-Specified dose on specified days
Azienda Ospedaliera Citta della Salute e della Scienza, Torino
Hopital De La Timone, Marseille
Istituto Nazionale Per La Ricerca Sul Cancro - Oncologia Med, Genova
Istituto Europeo Di Oncologia, Milan
Local Institution, Madrid
Hopital Trousseau - Chru Tours, Tours
Local Institution, Seville
Local Institution, Nantes
Istituto Scientifico Romagnolo Per Lo Studio E Cura Tumori, Meldola (FC)
Local Institution, Lyon
Hopital Saint Louis, Paris
Local Institution, Paris
Melanoma Institute Australia, North Sydney
Greenslopes Private Hospital, Greenslopes
Cabrini Hospital, Malvern
Local Institution, Barcelona
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY